报价延迟最少15分钟:2026/01/10 19:05 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.75 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.36/-0.38
|
|
企业价值
499.45M
|
| 资产负债 |
|
每股账面净值
-0.03
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
0.57
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300. |
